Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

被引：0
|
作者：
Hubert G. Nüßlein
Rieke Alten
Mauro Galeazzi
Hanns-Martin Lorenz
Michael T. Nurmohamed
William G. Bensen
Gerd R. Burmester
Hans-Hartmut Peter
Karel Pavelka
Melanie Chartier
Coralie Poncet
Christiane Rauch
Manuela Le Bars
机构：
[1] University of Erlangen-Nuremberg,Institute of Rheumatology and Clinic of Rheumatology
[2] Schlosspark-Klinik University Medicine,undefined
[3] University of Siena,undefined
[4] University Hospital,undefined
[5] VU University Medical Center/Jan van Breeman Research Institute,undefined
[6] St Joseph’s Hospital/McMaster University,undefined
[7] Charité-Universitätsmedizin,undefined
[8] University Medical Center Freiburg,undefined
[9] Charles University,undefined
[10] Chiltern International,undefined
[11] Docs International,undefined
[12] Bristol‐Myers Squibb,undefined
[13] Bristol-Myers Squibb,undefined
来源：
BMC Musculoskeletal Disorders | / 16卷
关键词：
Abatacept; Biologic agents; Cyclic citrullinated peptide; Heart failure; Prognostic factors; Multivariate analysis; Retention; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] BUDGET IMPACT ANALYSIS OF ZANUBRUTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY FROM THE PAYER PERSPECTIVE IN THE UNITED STATES
    Liu, R.
    Yeh, Y. C.
    Yang, K.
    Gao, X.
    Balk, M.
    Tang, B.
    [J]. VALUE IN HEALTH, 2020, 23 : S434 - S434
  • [22] COST MINIMIZATION ANALYSIS OF ZANUBRUTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY FROM THE PAYER PERSPECTIVE IN THE UNITED STATES
    Liu, R.
    Yeh, Y. C.
    Yang, H. K.
    Gao, X.
    Tang, B.
    [J]. VALUE IN HEALTH, 2020, 23 : S37 - S38
  • [23] RETENTION RATES AND CLINICAL OUTCOMES IN COHORTS OF PATIENTS (BIOLOGIC NAIVE OR FAILED PRIOR BIOLOGICS) TREATED WITH INTRAVENOUS ABATACEPT IN A REAL-WORLD SETTING: 6-MONTH RESULTS FROM THE ACTION STUDY
    Alten, R.
    Nuesslein, H.
    Galeazzi, M.
    Lorenz, H. -M.
    Mariette, X.
    Cantagrel, A.
    Chartier, M.
    Poncet, C.
    Rauch, C.
    Le Bars, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1056 - 1057
  • [24] A multicenter, prospective, observational cohort studies in incident dialysis patients:: Interim analysis results from the ANSWER study
    García, RP
    Martín-Malo, A
    Fort, J
    Cuevas, X
    García, F
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V296 - V296
  • [25] PATIENT REPORTED OUTCOMES (PROS) OF MULTIPLE MYELOMA (MM) PATIENTS FROM THE PANORAMA-1 STUDY WHO HAVE RECEIVED AT LEAST TWO PRIOR REGIMENS INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT
    Richardson, P. G.
    Hungria, V.
    Yoon, S. S.
    Beksac, M.
    Dimopoulos, M. A.
    Elghandour, A.
    Jedrzejczak, W. W.
    Jedrzejczak, W. W.
    Nakorn, T. N.
    Siritanaratkul, N.
    Schlossman, R.
    Hou, J.
    Moreau, P.
    Lonial, S.
    Lee, J. H.
    Einsele, H.
    Binlich, F.
    Sopala, M.
    Roy, A.
    Panneerselvam, A.
    San Miguel, J.
    [J]. HAEMATOLOGICA, 2016, 101 : 786 - 786
  • [26] Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi-institute study
    Ito, Toshiki
    Mizutani, Kosuke
    Takahara, Kiyoshi
    Ando, Ryosuke
    Yasui, Takahiro
    Shiroki, Ryoichi
    Koie, Takuya
    Miyake, Hideaki
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (01)
  • [27] REAL WORLD SKIN CLEARANCE RATES FOR BIOLOGIC TREATMENTS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: INTERIM RESULTS FROM A LARGE PROSPECTIVE, OBSERVATIONAL STUDY
    Paul, C.
    Bewley, A.
    Girolomoni, G.
    Reich, K.
    Puig, L.
    Lacour, J. P.
    Augustin, M.
    Naldi, L.
    Menter, A. M.
    Wade, S.
    Viswanathan, H. N.
    Palmer, K.
    Klekotka, P.
    Woolley, J. M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A429 - A429
  • [28] REAL WORLD STUDY OF BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG PERSISTENCE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE PREVIOUSLY USED AT LEAST ONE OTHER BIOLOGIC AGENT: A US ADMINISTRATIVE CLAIMS DATABASE ANALYSIS
    Johnston, S.
    McMorrow, D.
    Farr, A. M.
    Juneau, P.
    Ogale, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 774 - 774
  • [29] Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study
    Nuesslein, H. G.
    Alten, R.
    Galeazzi, M.
    Lorenz, H. -M.
    Nurmohamed, M. T.
    Bensen, W. G.
    Burmester, G. R.
    Peter, H. -H.
    Peichl, P.
    Pavelka, K.
    Chartier, M.
    Poncet, C.
    Rauch, C.
    Le Bars, M.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (03) : 489 - 499
  • [30] Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
    Hubert G Nüßlein
    Rieke Alten
    Mauro Galeazzi
    Hanns-Martin Lorenz
    Dimitrios Boumpas
    Michael T Nurmohamed
    William G Bensen
    Gerd R Burmester
    Hans-Hartmut Peter
    Franz Rainer
    Karel Pavelka
    Melanie Chartier
    Coralie Poncet
    Christiane Rauch
    Manuela Le Bars
    [J]. BMC Musculoskeletal Disorders, 15
12345